Wird geladen...
Gardos pathway to sickle cell therapies?
In this issue of Blood, Ataga and colleagues report that treatment of sickle cell disease patients with senicapoc, a Gardos channel inhibitor, reduces the number of dehydrated cells, increases hemoglobin levels, and diminishes hemolysis.
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
American Society of Hematology
2008
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2288713/ https://ncbi.nlm.nih.gov/pubmed/18434967 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-01-135350 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|